In the current study, we evaluated the immunogenicity and safety of INO-5150, a DNA vaccine encoding PSA and PSMA, with or without INO-9012 (encoding IL-12 immune adjuvant), in men with biochemically relapsed prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.